|
1
|
Robinson BW and Lake RA: Advances in
malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Musk AW and de Klerk NH: Epidemiology of
malignant mesothelioma in Australia. Lung Cancer. 45:S21–S23. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
et al: Phase III study of pemetrexed in combination with cisplatin
versus cisplatin alone in patients with malignant pleural
mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Borasio P, Berruti A, Bille A, et al:
Malignant pleural mesothelioma: clinicopathologic and survival
characteristics in a consecutive series of 394 patients. Eur J
Cardiothorac Surg. 33:307–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Flores RM, Zakowski M, Venkatraman E, et
al: Prognostic factors in the treatment of malignant pleural
mesothelioma at a large tertiary referral center. J Thorac Oncol.
2:957–965. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krug LM, Pass HI, Rusch VW, et al:
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin
followed by extrapleural pneumonectomy and radiation for malignant
pleural mesothelioma. J Clin Oncol. 27:3007–3013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herndon JE, Green MR, Chahinian AP, Corson
JM, Suzuki Y and Vogelzang NJ: Factors predictive of survival among
337 patients with mesothelioma treated between 1984 and 1994 by the
Cancer and Leukemia Group B. Chest. 113:723–731. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Neumann V, Rutten A, Scharmach M, Muller
KM and Fischer M: Factors influencing long-term survival in
mesothelioma patients-results of the German mesothelioma register.
Int Arch Occup Environ Health. 77:191–199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Metintas M, Metintas S, Ucgun I, et al:
Prognostic factors in diffuse malignant pleural mesothelioma:
effects of pretreatment clinical and laboratory characteristics.
Respir Med. 95:829–835. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baas P: Predictive and prognostic factors
in malignant pleural mesothelioma. Curr Opin Oncol. 15:127–130.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar-Singh S, Jacobs W, Dhaene K, et al:
Syndecan-1 expression in malignant mesothelioma: correlation with
cell differentiation, WT1 expression, and clinical outcome. J
Pathol. 186:300–305. 1998. View Article : Google Scholar
|
|
12
|
Edwards JG, Swinson DE, Jones JL, Waller
DA and O’Byrne KJ: EGFR expression: associations with outcome and
clinicopathological variables in malignant pleural mesothelioma.
Lung Cancer. 54:399–407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edwards JG, Faux SP, Plummer SM, et al:
Cyclooxygenase-2 expression is a novel prognostic factor in
malignant mesothelioma. Clin Cancer Res. 8:1857–1862.
2002.PubMed/NCBI
|
|
14
|
Lopez-Rios F, Chuai S, Flores R, et al:
Global gene expression profiling of pleural mesotheliomas:
overexpression of aurora kinases and P16/CDKN2A deletion as
prognostic factors and critical evaluation of microarray-based
prognostic prediction. Cancer Res. 66:2970–2979. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gordon GJ, Rockwell GN, Godfrey PA, et al:
Validation of genomics-based prognostic tests in malignant pleural
mesothelioma. Clin Cancer Res. 11:4406–4414. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shimizu E, Coxon A, Otterson GA, et al: RB
protein status and clinical correlation from 171 cell lines
representing lung cancer, extrapulmonary small cell carcinoma, and
mesothelioma. Oncogene. 9:2441–2448. 1994.PubMed/NCBI
|
|
17
|
Modi S, Kubo A, Oie H, Coxon AB,
Rehmatulla A and Kaye FJ: Protein expression of the RB-related gene
family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene. 19:4632–4639. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giacinti C and Giordano A: RB and cell
cycle progression. Oncogene. 25:5220–5227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cote RJ, Jhanwar SC, Novick S and Pellicer
A: Genetic alterations of the p53 gene are a feature of malignant
mesotheliomas. Cancer Res. 51:5410–5416. 1991.PubMed/NCBI
|
|
20
|
Wong L, Zhou J, Anderson D and Kratzke RA:
Inactivation of p16INK4a expression in malignant mesothelioma by
methylation. Lung Cancer. 38:131–136. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang CT, You L, Yeh CC, et al:
Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma
cells. J Natl Cancer Inst. 92:636–641. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boersma CJ, Bloemen M, Hendriks JM, van
Berkel EA, Olijve W and van Zoelen EJ: Homeobox proteins as signal
transduction intermediates in regulation of NCAM expression by
recombinant human bone morphogenetic protein-2 in osteoblast-like
cells. Mol Cell Biol Res Commun. 1:117–124. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ohira T, Gemmill RM, Ferguson K, et al:
WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci
USA. 100:10429–10434. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Riddle RD, Ensini M, Nelson C, Tsuchida T,
Jessell TM and Tabin C: Induction of the LIM homeobox gene Lmx1 by
WNT7a establishes dorsoventral pattern in the vertebrate limb.
Cell. 83:631–640. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Timmreck LS, Pan HA, Reindollar RH and
Gray MR: WNT7A mutations in patients with Mullerian duct
abnormalities. J Pediatr Adolesc Gynecol. 16:217–221. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bui TD, Lako M, Lejeune S, et al:
Isolation of a full-length human WNT7A gene implicated in limb
development and cell transformation, and mapping to chromosome
3p25. Gene. 189:25–29. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kirikoshi H and Katoh M: Expression of
WNT7A in human normal tissues and cancer, and regulation of WNT7A
and WNT7B in human cancer. Int J Oncol. 21:895–900. 2002.PubMed/NCBI
|
|
29
|
Raz DJ, Ray MR, Kim JY, et al: A multigene
assay is prognostic of survival in patients with early-stage lung
adenocarcinoma. Clin Cancer Res. 14:5565–5570. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fennell DA, Parmar A, Shamash J, et al:
Statistical validation of the EORTC prognostic model for malignant
pleural mesothelioma based on three consecutive phase II trials. J
Clin Oncol. 23:184–189. 2005. View Article : Google Scholar
|
|
31
|
Miller C, Degenhardt K and Sassoon DA:
Fetal exposure to DES results in de-regulation of Wnt7a during
uterine morphogenesis. Nat Genet. 20:228–230. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mericskay M, Kitajewski J and Sassoon D:
Wnt5a is required for proper epithelial-mesenchymal interactions in
the uterus. Development. 131:2061–2072. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Parr BA and McMahon AP: Sexually dimorphic
development of the mammalian reproductive tract requires Wnt-7a.
Nature. 395:707–710. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li S, Chiang TC, Davis GR, Williams RM,
Wilson VP and McLachlan JA: Decreased expression of Wnt7a mRNA is
inversely associated with the expression of estrogen receptor-alpha
in human uterine leiomyoma. J Clin Endocrinol Metab. 86:454–457.
2001.PubMed/NCBI
|
|
35
|
Pinton G, Brunelli E, Murer B, et al:
Estrogen receptor-beta affects the prognosis of human malignant
mesothelioma. Cancer Res. 69:4598–4604. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abate-Shen C: Deregulated homeobox gene
expression in cancer: cause or consequence? Nat Rev Cancer.
2:777–785. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Andujar P, Wang J, Descatha A, et al:
p16INK4A inactivation mechanisms in non-small-cell lung cancer
patients occupationally exposed to asbestos. Lung Cancer. 67:23–30.
2010. View Article : Google Scholar
|
|
38
|
Becklake MR, Thomas D, Liddell F and
McDonald JC: Follow-up respiratory measurements in Quebec
chrysotile asbestos miners and millers. Scand J Work Environ
Health. 8:105–110. 1982.PubMed/NCBI
|
|
39
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Flores EM: Induction chemotherapy,
extrapleural pneumonectomy, and radiotherapy in the treatment of
malignant pleural mesothelioma: the Memorial Sloan-Kettering
experience. Lung Cancer. 49:S71–S74. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tsao AS, Mehran R and Roth JA: Neoadjuvant
and intrapleural therapies for malignant pleural mesothelioma. Clin
Lung Cancer. 10:36–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Weder W, Kestenholz P, Taverna C, et al:
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in
malignant pleural mesothelioma. J Clin Oncol. 22:3451–3457. 2004.
View Article : Google Scholar : PubMed/NCBI
|
